Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure

International Journal of Urology

Volumn 15, Issue 5, 2008, Pages 407-415

  Schulte Baukloh, Heinrich ^a   Bigalke, Hans ^b   Miller, Kurt ^c   Heine, Gert ^a   Pape, Daniela ^a   Lehmann, Jan ^d   Knispel, Helmut H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Stadtisches Krankenhaus Kiel   (Germany)

Author keywords

Antibody; Botox; Botulinum toxin type A; Urinary bladder; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A ANTIBODY; TOXIN ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DETRUSOR MUSCLE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; URINE INCONTINENCE;

ADOLESCENT; ADULT; AGED; ANTIBODIES; BOTULINUM TOXIN TYPE A; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE; URINARY INCONTINENCE;

EID: 43049134099     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02016.x     Document Type: Article

References (18)

1. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988 139 : 919 22.
2. Schurch B, de Seze M, Denys P et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. 2005 174 : 196 200.
3. Chancellor M, O'Leary M, Erickson J et al. Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J. Urol. 2003 169 (Suppl 4 351.
4. Schulte-Baukloh H, Weiss C, Stolze T et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur. Urol. 2005 48 : 984 90.
5. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov. Disord. 2004 19 (Suppl 8 S92 100.
6. Schulte-Baukloh H, Bigalke H, Heine G et al. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection. Urology 2007 69 : 575.e13 15.
7. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies - therapeutic consequences. Exp. Neurol. 1997 147 : 96 102.
8. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur. Urol. 2006 50 : 684 709.
9. Pistolesi D, Selli C, Rossi B, Stampacchia G. Botulinum toxin type B for type A resistant bladder spasticity. J. Urol. 2004 171 : 802 3.
10. Reitz A, Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J. Urol. 2004 171 : 804 5.
11. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur. Urol. 2005 47 : 653 9.
12. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003 60 : 1186 8.
13. Comella CC, Chicago IL, Jankovic J. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type a treatment for cervical dystonia. Neurology 2004 62 (Suppl A511, poster 06.141.
14. Dressler D, Dirnberger G, Bhatia KP et al. Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov. Disord. 2000 15 : 973 6.
15. Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov. Disord. 2006 21 : 1737 41.
16. Lazzeri M. The physiological function of the urothelium - more than a simple barrier. Urol. Int. 2006 76 : 289 95.
17. Dressler D, Bigalke H. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov. Disord. 2002 17 : 170 3.
18. Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur. Neurol. 2002 47 : 118 21.